Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. reported first-quarter 2026 results showing early commercial traction but higher losses. Total revenue was $3.53 million, up 21% year over year, driven by a jump in ZUNVEYL product sales to $3.50 million, while licensing revenue fell to $0.03 million.
Operating expenses rose to $11.63 million, mainly from expanding sales, marketing, and headcount to support the ZUNVEYL launch, resulting in a net loss of $6.48 million versus $1.73 million a year earlier. Cash and cash equivalents were $54.25 million, and management believes this is sufficient for at least 12 months, though additional capital will likely be needed for ongoing commercialization and R&D.
The company disclosed a material weakness in internal control over financial reporting related to complex instruments and segregation of duties and is implementing enhanced review procedures and external technical support. Alpha Cognition remains focused on building the ZUNVEYL franchise and advancing its preclinical neurodegenerative pipeline.
Alpha Cognition Inc. files Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership stakes held by affiliated entities and individuals. The filing lists Manchester Management Company, LLC with 919,935 shares (4.2%), Manchester Management PR, LLC with 919,935 shares (4.2%), James E. Besser with 1,076,935 shares (4.9%), and Morgan C. Frank with 888,935 shares (4.0%).
The filing states that all reported securities are directly owned by advisory clients of Manchester Management PR, LLC and includes a Joint Filing Agreement. The signatures are dated 05/12/2026.
Alpha Cognition Inc. amendment to a joint Schedule 13G/A reports that Opaleye-linked reporting persons beneficially own 2,561,950 shares of common stock, representing 11.77% of the class. The filing attributes shared voting and dispositive power over those shares, and cites 21,774,104 shares outstanding as of 03/31/2026 from Alpha Cognition's Form 10-K.
The statement is filed jointly by Opaleye Management Inc., Opaleye, L.P., and James Silverman and clarifies the adviser/fund relationship and voting/dispositive arrangements for the reported holdings.
Alpha Cognition Inc. filed an amended report to update details about director Bethany Sensenig’s board roles. On April 28, 2026, the Board appointed her to the Audit Committee and the Governance and Nomination Committee. Following the annual meeting of shareholders on June 16, 2026, she will become Chair of the Audit Committee.
Alpha Cognition Inc. is asking shareholders at its June 16, 2026 annual meeting in Texas to fix the Board size at six directors, elect six nominees, and approve CBIZ CPAs P.C. as independent auditors for the year ending December 31, 2026.
Current chair Len Mertz will not stand for re-election, and the Board has selected Robert Wills to become the next non-executive chair. The proxy details ownership of 21,774,104 common shares and 316,655 Class B preferred Series A shares as of April 24, 2026, with directors and officers holding 8.6% of common shares and 9.5% of total voting stock.
The filing outlines governance practices, Board and committee composition, audit committee qualifications, and compensation for key executives, including 2025 total pay of $3.6 million for CEO Michael McFadden and $2.4 million for COO Lauren D’Angelo. It also describes the 2025 transition of audit work from Manning Elliott to CBIZ, characterized as an administrative change following the move of principal offices to Texas with no reported disagreements on accounting or auditing matters.
Alpha Cognition Inc. appointed Bethany Sensenig to its board of directors effective April 15, 2026. She brings senior finance and operations experience from roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and a 13-year career at Biogen with P&L responsibility over about $1 billion in annual revenue across 30 countries.
As a non-employee director, she will be compensated under the company’s standard policy and received an initial equity grant of 5,489 restricted stock units and 6,991 stock options, with an exercise price of $6.65 per share. Both the RSUs and options vest one year after the grant date. The company states there are no arrangements, family relationships, or related-party transactions linked to her appointment.
Alpha Cognition Inc. director Bethany Sensenig reported equity awards consisting of stock options and restricted stock units as compensation. She received 6,991 Common Share Options at an exercise price of $6.65 per share, expiring on April 16, 2036, which will vest one year from the grant date. She also received 5,489 Common Shares in the form of restricted stock units that vest one year from the grant date. After these awards, her reported holdings are 6,991 options and 5,489 common shares held directly, and there were no open-market purchases or sales in this filing.
Alpha Cognition Inc. director Bethany Sensenig filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The excerpt shows no reported transactions, no derivative positions, and no listed holdings, indicating this filing is purely administrative disclosure at this time.
Alpha Cognition Inc. entered into a settlement agreement with Galantos Pharma GmbH to eliminate future contingent payment obligations tied to the Memogain asset and technology agreements. The company will make a one-time payment of EUR 5,214,220 to fully satisfy remaining royalty and milestone-related obligations under the Original Agreement.
In exchange for this lump-sum payment, Galantos will waive and release all related claims against Alpha Cognition and its affiliates. The settlement amount is described as representing an approximate 40% discount to the estimated market value of the remaining obligations, based on management’s assessment of projected future payments and comparable market benchmarks.
Alpha Cognition Inc. is a biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s. It has shifted from pure R&D to commercialization with the U.S. launch of ZUNVEYL, an oral acetylcholinesterase inhibitor for mild-to-moderate Alzheimer’s disease, on March 19, 2025.
The company is targeting the long-term care market, where acetylcholinesterase inhibitors account for a large share of more than 11 million annual U.S. prescriptions. ZUNVEYL’s wholesale acquisition cost is set at $820 per month, and Alpha Cognition is negotiating coverage with major pharmacy benefit managers.
Beyond ZUNVEYL, the pipeline includes a fixed-dose combination of ALPHA‑1062 and memantine for moderate-to-severe Alzheimer’s, a sublingual ALPHA‑1062 formulation for patients with swallowing difficulties, and programs in mild traumatic brain injury. A broad patent estate provides protection into the 2040s across multiple jurisdictions and formulations.